DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the AKUMS DRUGS AND PHARMA L (AKUMS) share price today?

AKUMS DRUGS AND PHARMA L (AKUMS) is trading at ₹664.95 on the NSE, down 2.64% on the day. Source: DocStoX.

What is the PE ratio of AKUMS DRUGS AND PHARMA L?

AKUMS DRUGS AND PHARMA L has a price-to-earnings (PE) ratio of 41.0 in the Healthcare sector.

What is the market capitalisation of AKUMS DRUGS AND PHARMA L?

AKUMS DRUGS AND PHARMA L has a market capitalisation of approximately ₹10,504 crore.

AKUMS DRUGS AND PHARMA L

AKUMS·NSE·Healthcare

₹664.95▼ -18.00 (-2.64%)

Healthcare · Pharmaceuticals

A steady, established business

Day₹650.25

₹681.95

52W₹409

₹71584%

Open

₹679.00

High

₹681.95

Low

₹650.25

Prev Close

₹682.95

Volume

4.17L

VWAP

₹661.68

Snapshot

Key fundamentals

Market Cap

₹10,504 Cr

P/E Ratio

41.02Expensive

P/B Ratio

3.02

EPS

₹16.21

Book Value

₹211.00

ROE

8.45%Average

ROCE

15.00%Decent

Dividend Yield

0.46%

Debt / Equity

0.05Low

Face Value

₹2.00

52W High

₹714.70

52W Low

₹409.30

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

None moatMedium uncertainty

Fair value estimate

₹219

▼ 67.1%downside

Trading at ₹665 — 67% above our estimate

BearFair valueBull

₹186₹219₹277

/100

Business quality — Watch the fundamentals

Growth 62Profitability 19Efficiency 18Valuation 60

Plain English

Our view

A steady, established business
Virtually debt-free balance sheet
Fundamental red flags (Piotroski 0/9)

Strengths

Virtually debt-free balance sheet
Profit growing 38% a year
Promoters hold a controlling stake

Risks

Fundamental red flags (Piotroski 0/9)

How we got there

Fair value methods

Residual income

8% ROE fading to 12% over ~3 yrs, on ₹211 book

₹203

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹277

Analyst target

No analyst coverage

—

Blended fair value₹219

What the numbers say

Investment thesis

Bull case

Virtually debt-free balance sheet
Profit growing 38% a year
Promoters hold a controlling stake

Bear case

Fundamental red flags (Piotroski 0/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

41.0Expensive

Below 15× is value territory; above 35× prices in strong growth

ROE

8.4%Average

Above 15% is considered healthy for Indian equities

ROCE

15.0%Decent

Above 18% means capital is working hard

Debt/Eq

0.05Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹10,504 Cr

P/B

3.02

EPS

₹16.21

Div Yield

0.46%

What changed

Recent changes

Foreign investors+0.2% stake last quarter

What matters

News impact

Overview

Valuation

Expensive

P/E 41.0×

Growth

Steady

+6% rev CAGR

Profitability

Modest

8.4% ROE

Financial health

Rock solid

D/E 0.05

Momentum

N/A

No technicals

Today

Trading activity

Delivery %52.5%

Turnover₹2760.99L Cr

Trades23,032

VWAP₹661.68

Face value₹2.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+6.0%

+9.9%

10Y

+11.5%

Profit

+37.7%

+15.8%

10Y

+19.5%

EPS

+34.7%

-55.6%

10Y

-26.8%

Profile

Pros

Company is almost debt free.

Watch-outs

Cons

Stock is trading at 3.33 times its book value
The company has delivered a poor sales growth of 9.87% over past five years.
Company has a low return on equity of 9.89% over last 3 years.

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Foreign investors bought 0.24 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

75%

Promoter

Promoters

75.3%0.00

Public

6.3%-0.16

FII / FPI

1.4%+0.24

DII

14.4%-0.05

Others

2.7%

Total shareholders

72,589-4,280 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter75.26%

FII1.38%

DII14.36%

Public6.29%

Others2.71%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions